<sup>225</sup>Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
177Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic prostate cancer (mCRPC) with proven efficacy. 225Ac-PCMA-617 is an alpha emitter, making this drug potentially more powerful. Despite the active use of 225Ac-PSMA-617 worldwide, no randomized phase III...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Russo |
| Gepubliceerd in: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2025-01-01
|
| Reeks: | Сибирский онкологический журнал |
| Onderwerpen: | |
| Online toegang: | https://www.siboncoj.ru/jour/article/view/3360 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|